Structure-activity relationships and in silico models of P-glycoprotein (ABCB1) inhibitors

Xenobiotica

Volumn 43, Issue 11, 2013, Pages 1018-1026

  Liu, Hongming ^a   Ma, Zhiguo ^a   Wu, Baojian ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Drug discovery; P glycoprotein; SAR; Structure transport relationships; Transporters

Indexed keywords

4 PHENYLPIPERIDINE DERIVATIVE; BENZOPHENONE DERIVATIVE; CITALOPRAM; DESVENLAFAXINE; FLUOXETINE; FLUVOXAMINE; GLYCOPROTEIN P INHIBITOR; HYDROXYL GROUP; IMIDAZOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1 INHIBITOR; NORCITALOPRAM; NORFLUOXETINE; NORSERTRALINE; PAROXETINE; PHENOTHIAZINE DERIVATIVE; PROPAFENONE; QUINAZOLINONE DERIVATIVE; REBOXETINE; RESERPINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TARIQUIDAR; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VENLAFAXINE; VERAPAMIL; VINBLASTINE; XR 9544; ZOSUQUIDAR;

BINDING SITE; BLOOD BRAIN BARRIER; CANCER CELL; CANCER RESISTANCE; COMPUTER MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; HYDROGEN BOND; IC 50; LIPOPHILICITY; MOLECULAR DOCKING; MOLECULAR MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOPHORE; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOPHENONES; COMPUTER SIMULATION; HUMANS; MODELS, MOLECULAR; P-GLYCOPROTEIN; PROPAFENONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885089993     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.791003     Document Type: Review

References (60)

1. Aller SG, Yu J, Ward A, et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-22
2. Benet LZ. (2009). The drug transporter-metabolism alliance: Uncovering and defining the interplay. Mol Pharm 6:1631-43
3. Chang C, Bahadduri PM, Polli JE, et al. (2006). Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 34: 1976-84
4. Chen L, Li Y, Yu H, et al. (2012). Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov Today 17: 343-51
5. Chiba P, Ecker G, Schmid D, et al. (1996). Structural requirements for activity of propafenone-Type modulators in P-glycoprotein-mediated multidrug resistance. Mol Pharmacol 49:1122-30
6. Chiba P, Hitzler M, Richter E, et al. (1997). Studies on propafenone-Type modulators of multidrug resistance III: Variations on the nitrogen. Quant Struct-Act Relat 16:361-6
7. Colabufo NA, Berardi F, Cantore M, et al. (2008). Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg Med Chem 16:362-73
8. Dantzig AH, Shepard RL, Cao J, et al. (1996). Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171-9
9. Dolghih E, Bryant C, Renslo AR, Jacobson MP (2011). Predicting binding to p-glycoprotein by flexible receptor docking. PLoS Comput Biol 7:e1002083
10. Ekins S, Kim RB, Leake BF, et al. (2002). Three-dimensional quantitative structure-Activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61:964-73
11. Ford JM, Bruggemann EP, Pastan I, et al. (1990). Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50:1748-56
12. Ford JM, Prozialeck WC, Hait WN. (1989). Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35:105-15
13. Fromm MF. (2000). P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69-74
14. Gatlik-Landwojtowicz E, Aänismaa P, Seelig A. (2006). Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 45:3020-32
15. Globisch C, Pajeva IK, Wiese M. (2006). Structure-Activity relationships of a series of tariquidar analogs as multidrug resistance modulators. Bioorg Med Chem 14:1588-98
16. Hochman J, Mei Q, Yamazaki M, et al. (2006). Role of mechanistic transport studies in lead optimization. In: Borchardt RT, Kerns EH, Hageman MJ, et al., eds. Optimizing the ''drug-like'' properties of leads in drug discovery. New York: Springer, 25-48
17. Jabeen I, Pleban K, Rinner U, et al. (2012). Structure-Activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-Type inhibitors of the multidrug transporter P-glycoprotein. J Med Chem 55:3261-73
18. Kim KH. (2001). 3D-QSAR analysis of 2,4,5- and 2,3,4,5-substituted imidazoles as potent and nontoxic modulators of P-glycoprotein mediated MDR. Bioorg Med Chem 9:1517-23
19. Kim RB, Fromm MF, Wandel C, et al. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-94
20. Klepsch F, Chiba P, Ecker GF. (2011). Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. PLoS Comput Biol 7:e1002036
21. Lagunin A, Gloriozova T, Dmitriev A, et al. (2013). Computer evaluation of drug interactions with P-glycoprotein. Bull Exp Biol Med 154:521-4
22. Lam FC, Liu R, Lu P, et al. (2001). Beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 76:1121-8
23. Langer T, Eder M, Hoffmann RD, et al. (2004). Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Arch Pharm (Weinheim) 337:317-27
24. Lee JY, Urbatsch IL, Senior AE, Wilkens S. (2008). Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy. J Biol Chem 283:5769-79
25. Leong MK, Chen HB, Shih YH. (2012). Prediction of promiscuous p-glycoprotein inhibition using a novel machine learning scheme. PLoS One 7:e33829
26. Ling V, Kartner N, Sudo T, et al. (1983). Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 67:869-74
27. Locher KP. (2009). Structure and mechanism of ATP-binding cassette transporters. Philos Trans R Soc Lond B Biol Sci 364:239-45
28. Longley DB, Johnston PG. (2005). Molecular mechanisms of drug resistance. J Pathol 205:275-92
29. Loo TW, Bartlett MC, Clarke DM. (2003). Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem 278:39706-10
30. Martin C, Berridge G, Higgins CF, et al. (2000). Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624-32
31. Müller H, Pajeva IK, Globisch C, Wiese M. (2008). Functional assay and structure-Activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem 16:2448-62
32. Oldham ML, Davidson AL, Chen J. (2008). Structural insights into ABC transporter mechanism. Curr Opin Struct Biol 18:726-33
33. Pajeva I, Wiese M. (1998). Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study. J Med Chem 41:1815-26
34. Pajeva IK, Globisch C, Wiese M. (2004). Structure-function relationships of multidrug resistance P-glycoprotein. J Med Chem 47:2523-33
35. Pajeva IK, Globisch C, Wiese M. (2009). Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors. ChemMedChem 4:1883-96
36. Pajeva IK, Wiese M. (2009). Structure-Activity relationships of tariquidar analogs as multidrug resistance modulators. AAPS J 11: 435-44
37. Palmeira A, Sousa E, Vasconcelos MH, et al. (2012a). Structure and ligand-based design of P-glycoprotein inhibitors: A historical perspective. Curr Pharm Des 18:4197-214
38. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. (2012b). Three decades of P-gp inhibitors: Skimming through several generations and scaffolds. Curr Med Chem 19:1946-2025
39. Pearce HL, Safa AR, Bach NJ, et al. (1989). Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci U S A 86:5128-32
40. Ramachandra M, Ambudkar SV, Chen D, et al. (1998). Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37:5010-19
41. Ramu A, Ramu N. (1992). Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 30:165-73
42. Raviv Y, Pollard HB, Bruggemann EP, et al. (1990). Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265:3975-80
43. Roe M, Folkes A, Ashworth P, et al. (1999). Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9:595-600
44. Rosenberg MF, Kamis AB, Callaghan R, et al. (2003). Threedimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 278: 8294-9
45. Rosenberg MF, Velarde G, Ford RC, et al. (2001). Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 20:5615-25
46. Salphati L. (2009). Transport-metabolism interplay. Mol Pharm 6: 1629-30
47. Sarshar S, Zhang C, Moran EJ, et al. (2000). 2,4,5-Trisubstituted imidazoles: Novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 1. Bioorg Med Chem Lett 10:2599-601
48. Sauna ZE, Ambudkar SV. (2007). About a switch: How P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther 6:13-23
49. Schinkel AH. (1999). P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179-94
50. Schmid D, Ecker G, Kopp S, et al. (1999). Structure-Activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem Pharmacol 58:1447-56
51. Seelig A, Landwojtowicz E. (2000). Structure-Activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31-40
52. Sharom FJ. (2008). ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9:105-27
53. Sharom FJ. (2011). The P-glycoprotein multidrug transporter. Essays Biochem 50:161-78
54. Stȩpień KM, Tomaszewski M, Tomaszewska J, Czuczwar SJ. (2012). The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep 64:1011-19
55. Tombline G, Muharemagić A, White LB, Senior AE. (2005). Involvement of the ''occluded nucleotide conformation'' of P-glycoprotein in the catalytic pathway. Biochemistry 44:12879-86
56. Tsakovska IM. (2003). QSAR and 3D-QSAR of phenothiazine type multidrug resistance modulators in P388/ADR cells. Bioorg Med Chem 11:2889-99
57. Wang S, Ryder H, Pretswell I, et al. (2002). Studies on quinazolinones as dual inhibitors of P-gp and MRP1 in multidrug resistance. Bioorg Med Chem Lett 12:571-4
58. Weiss J, Dormann SM, Martin-Facklam M, et al. (2003). Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305: 197-204
59. Zamora JM, Pearce HL, Beck WT. (1988). Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33:454-62
60. Zhang C, Sarshar S, Moran EJ, et al. (2000). 2,4,5-Trisubstituted imidazoles: Novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2. Bioorg Med Chem Lett 10:2603-5